Diabetes drug development now involves more complex, lengthy and costly studies with intense competition to recruit and retain the right patients.
Axzons has the experience and expertise to provide you with strategic and practical solutions in endocrinal diseases and metabolism for your development journey.
Your goal is to develop new diabetes medications to help address the unmet needs of more than 366 million individual living with diabetes worldwide. The complexities of a crowded diabetes pipeline and intense competition to enrol the right patients in diabetes trials demand a committed, experienced partner to navigate this complex landscape.
Axzons can provide the collaborative guidance to progress your diabetes drug development program across the lifecycle from concept through commercialization. As your partner in diabetes clinical trial execution, we can complement your resources by delivering proven therapeutic and scientific expertise to efficiently plan and execute your studies.Axzons’s global reach, therapeutic expertise and operational excellence can help increase the probability of your success:
- Global Expertise in Endocrinal and Metabolic Diseases – in the past years, we provided services for many Endocrinal and Metabolic Diseases studies involving thousands of subjects and investigator sites in Europe and Asia
- Therapeutic Leadership – Axzons helped develop or commercialize 100% of 2012’s top 20 best-selling Diabetes products or compounds
- Our strong global expertise in endocrinal and metabolic Diseases provides you with a virtual, cross-functional team of therapeutic, scientific and operational experts who integrate their specialized knowledge with data-driven insights to optimize your diabetes drug development
- Patient Recruitment and Retention – Diabetes clinical trial enrolment poses a major challenge given the intense competition to enrol patients. Axzons can help you recruit the right patient faster. In Phase II, III and IIIb diabetes studies that’s the potential to generate an additional $95 million in revenue.